Longeveron (LGVN) Gross Margin (2020 - 2026)

Longeveron (LGVN) recorded quarterly Gross Margin of 66.33% in Q1 2026, down 5.79% quarter-over-quarter from 70.41% in Q4 2025, and down 585.0% on a YoY basis from 13.68% in Q1 2025.

Longeveron (LGVN) Gross Margin (2020 - 2026) Analysis & Trends

Longeveron's Gross Margin history runs 7 years deep, the most recent figure standing at 66.33% for Q1 2026.

  • In Q1 2026, Gross Margin fell 585.0% year-over-year to 66.33%; the TTM figure through Mar 2026 stood at 65.13% (down 1716.0% YoY), while the FY2025 annual figure was 66.97%, down 1179.0% from the prior year.
  • Gross Margin was 66.33% for Q1 2026 at Longeveron, down from 70.41% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 92.0% in Q3 2022 to a low of 45.45% in Q4 2022.
  • Historically, Gross Margin has averaged 52.02% across 5 years, with a median of 60.04% in 2024.
  • The sharpest annual moves came in 2022 and 2024: Gross Margin slumped 7847 bps in 2022, then surged 9107 bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 45.45% in 2022, then soared by 93 bps to 3.17% in 2023, then jumped by 2869 bps to 87.89% in 2024, then decreased by 20 bps to 70.41% in 2025, then retreated by 6 bps to 66.33% in 2026.
  • The last three Gross Margin figures came in at 66.33% (Q1 2026), 70.41% (Q4 2025), and 91.24% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 79.04%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 86.85%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 66.33%

Historic Data

Download Data
DateValue
Mar 31, 2026 66.33%
Dec 31, 2025 70.41%
Sep 30, 2025 91.24%
Jun 30, 2025 46.20%
Mar 31, 2025 72.18%
Dec 31, 2024 87.89%
Sep 30, 2024 88.23%
Jun 30, 2024 73.50%
Mar 31, 2024 60.04%
Dec 31, 2023 -3.17%
Sep 30, 2023 36.00%
Jun 30, 2023 42.86%
Mar 31, 2023 27.24%
Dec 31, 2022 -45.45%
Sep 30, 2022 92.00%
Jun 30, 2022 34.33%
Mar 31, 2022 44.59%
Dec 31, 2021 33.01%
Sep 30, 2021 70.69%
Jun 30, 2021 42.54%